40 years of IGF1: IGF1: The Jekyll and Hyde of the aging brain

Sriram Gubbi, Gabriela Farias Quipildor, Nir Barzilai, Derek M. Huffman, Sofiya Milman

Research output: Contribution to journalReview article

  • 1 Citations

Abstract

The insulin-like growth factor 1 (IGF1) signaling pathway has emerged as a major regulator of the aging process, from rodents to humans. However, given the pleiotropic actions of IGF1, its role in the aging brain remains complex and controversial. While IGF1 is clearly essential for normal development of the central nervous system, conflicting evidence has emerged from preclinical and human studies regarding its relationship to cognitive function, as well as cerebrovascular and neurodegenerative disorders. This review delves into the current state of the evidence examining the role of IGF1 in the aging brain, encompassing preclinical and clinical studies. A broad examination of the data indicates that IGF1 may indeed play opposing roles in the aging brain, depending on the underlying pathology and context. Some evidence suggests that in the setting of neurodegenerative diseases that manifest with abnormal protein deposition in the brain, such as Alzheimer’s disease, reducing IGF1 signaling may serve a protective role by slowing disease progression and augmenting clearance of pathologic proteins to maintain cellular homeostasis. In contrast, inducing IGF1 deficiency has also been implicated in dysregulated function of cognition and the neurovascular system, suggesting that some IGF1 signaling may be necessary for normal brain function. Furthermore, states of acute neuronal injury, which necessitate growth, repair and survival signals to persevere, typically demonstrate salutary effects of IGF1 in that context. Appreciating the dual, at times opposing ‘Dr Jekyll’ and ‘Mr Hyde’ characteristics of IGF1 in the aging brain, will bring us closer to understanding its impact and devising more targeted IGF1-related interventions.

LanguageEnglish (US)
PagesT171-T185
JournalJournal of Molecular Endocrinology
Volume61
Issue number1
DOIs
StatePublished - Jul 1 2018

Fingerprint

Somatomedins
Brain
Neurodegenerative Diseases
Cognition
Cerebrovascular Disorders
Disease Progression
Rodentia
Alzheimer Disease
Proteins
Homeostasis
Central Nervous System
Pathology
Survival

Keywords

  • Alzheimer’s
  • CNS
  • Cognition
  • Parkinson’s

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology

Cite this

40 years of IGF1 : IGF1: The Jekyll and Hyde of the aging brain. / Gubbi, Sriram; Quipildor, Gabriela Farias; Barzilai, Nir; Huffman, Derek M.; Milman, Sofiya.

In: Journal of Molecular Endocrinology, Vol. 61, No. 1, 01.07.2018, p. T171-T185.

Research output: Contribution to journalReview article

@article{0561029cb0e04352a6a02b2da3527b43,
title = "40 years of IGF1: IGF1: The Jekyll and Hyde of the aging brain",
abstract = "The insulin-like growth factor 1 (IGF1) signaling pathway has emerged as a major regulator of the aging process, from rodents to humans. However, given the pleiotropic actions of IGF1, its role in the aging brain remains complex and controversial. While IGF1 is clearly essential for normal development of the central nervous system, conflicting evidence has emerged from preclinical and human studies regarding its relationship to cognitive function, as well as cerebrovascular and neurodegenerative disorders. This review delves into the current state of the evidence examining the role of IGF1 in the aging brain, encompassing preclinical and clinical studies. A broad examination of the data indicates that IGF1 may indeed play opposing roles in the aging brain, depending on the underlying pathology and context. Some evidence suggests that in the setting of neurodegenerative diseases that manifest with abnormal protein deposition in the brain, such as Alzheimer’s disease, reducing IGF1 signaling may serve a protective role by slowing disease progression and augmenting clearance of pathologic proteins to maintain cellular homeostasis. In contrast, inducing IGF1 deficiency has also been implicated in dysregulated function of cognition and the neurovascular system, suggesting that some IGF1 signaling may be necessary for normal brain function. Furthermore, states of acute neuronal injury, which necessitate growth, repair and survival signals to persevere, typically demonstrate salutary effects of IGF1 in that context. Appreciating the dual, at times opposing ‘Dr Jekyll’ and ‘Mr Hyde’ characteristics of IGF1 in the aging brain, will bring us closer to understanding its impact and devising more targeted IGF1-related interventions.",
keywords = "Alzheimer’s, CNS, Cognition, Parkinson’s",
author = "Sriram Gubbi and Quipildor, {Gabriela Farias} and Nir Barzilai and Huffman, {Derek M.} and Sofiya Milman",
year = "2018",
month = "7",
day = "1",
doi = "10.1530/JME-18-0093",
language = "English (US)",
volume = "61",
pages = "T171--T185",
journal = "Journal of Molecular Endocrinology",
issn = "0952-5041",
publisher = "Society for Endocrinology",
number = "1",

}

TY - JOUR

T1 - 40 years of IGF1

T2 - Journal of Molecular Endocrinology

AU - Gubbi, Sriram

AU - Quipildor, Gabriela Farias

AU - Barzilai, Nir

AU - Huffman, Derek M.

AU - Milman, Sofiya

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The insulin-like growth factor 1 (IGF1) signaling pathway has emerged as a major regulator of the aging process, from rodents to humans. However, given the pleiotropic actions of IGF1, its role in the aging brain remains complex and controversial. While IGF1 is clearly essential for normal development of the central nervous system, conflicting evidence has emerged from preclinical and human studies regarding its relationship to cognitive function, as well as cerebrovascular and neurodegenerative disorders. This review delves into the current state of the evidence examining the role of IGF1 in the aging brain, encompassing preclinical and clinical studies. A broad examination of the data indicates that IGF1 may indeed play opposing roles in the aging brain, depending on the underlying pathology and context. Some evidence suggests that in the setting of neurodegenerative diseases that manifest with abnormal protein deposition in the brain, such as Alzheimer’s disease, reducing IGF1 signaling may serve a protective role by slowing disease progression and augmenting clearance of pathologic proteins to maintain cellular homeostasis. In contrast, inducing IGF1 deficiency has also been implicated in dysregulated function of cognition and the neurovascular system, suggesting that some IGF1 signaling may be necessary for normal brain function. Furthermore, states of acute neuronal injury, which necessitate growth, repair and survival signals to persevere, typically demonstrate salutary effects of IGF1 in that context. Appreciating the dual, at times opposing ‘Dr Jekyll’ and ‘Mr Hyde’ characteristics of IGF1 in the aging brain, will bring us closer to understanding its impact and devising more targeted IGF1-related interventions.

AB - The insulin-like growth factor 1 (IGF1) signaling pathway has emerged as a major regulator of the aging process, from rodents to humans. However, given the pleiotropic actions of IGF1, its role in the aging brain remains complex and controversial. While IGF1 is clearly essential for normal development of the central nervous system, conflicting evidence has emerged from preclinical and human studies regarding its relationship to cognitive function, as well as cerebrovascular and neurodegenerative disorders. This review delves into the current state of the evidence examining the role of IGF1 in the aging brain, encompassing preclinical and clinical studies. A broad examination of the data indicates that IGF1 may indeed play opposing roles in the aging brain, depending on the underlying pathology and context. Some evidence suggests that in the setting of neurodegenerative diseases that manifest with abnormal protein deposition in the brain, such as Alzheimer’s disease, reducing IGF1 signaling may serve a protective role by slowing disease progression and augmenting clearance of pathologic proteins to maintain cellular homeostasis. In contrast, inducing IGF1 deficiency has also been implicated in dysregulated function of cognition and the neurovascular system, suggesting that some IGF1 signaling may be necessary for normal brain function. Furthermore, states of acute neuronal injury, which necessitate growth, repair and survival signals to persevere, typically demonstrate salutary effects of IGF1 in that context. Appreciating the dual, at times opposing ‘Dr Jekyll’ and ‘Mr Hyde’ characteristics of IGF1 in the aging brain, will bring us closer to understanding its impact and devising more targeted IGF1-related interventions.

KW - Alzheimer’s

KW - CNS

KW - Cognition

KW - Parkinson’s

UR - http://www.scopus.com/inward/record.url?scp=85051084343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051084343&partnerID=8YFLogxK

U2 - 10.1530/JME-18-0093

DO - 10.1530/JME-18-0093

M3 - Review article

VL - 61

SP - T171-T185

JO - Journal of Molecular Endocrinology

JF - Journal of Molecular Endocrinology

SN - 0952-5041

IS - 1

ER -